biosimilar


Also found in: Dictionary, Wikipedia.

biosimilar

(bī′ō-sĭm′ə-lər)
adj.
Highly similar in function and effect to an existing biological product, especially to a biologic that has already been clinically tested and approved for use.
n.
A biological product that is biosimilar to an existing product, especially to a biologic.

biosimilar

adjective Referring to a biosimilar therapeutics agent.
 
noun A biopharmaceutical which is produced by a different manufacturer after the expiration of the patent and marketing exclusivity of an original innovative biological product (e.g., a therapeutic monoclonal antibody).
 
In contrast to small (non-biological) agents, for which manufacturing an equivalent product is a relatively straightforward chemical process, biosimilars are not produced from the original clones and cell lines used to produce the tested and proven-effective agent; they thus may have therapeutic and metabolic profiles that differ from the clinically tested and proven products.

biosimilar

(bi?o-sim'i-lar) [ bio- + similar]
1. A generic version of a biologically active pharmaceutical agent, e.g., of a manufactured antibody or hormone.
2. Pert. to such a generic version.
Synonym: follow-on biologicbiosimilarity
References in periodicals archive ?
Sandoz, a Germany-based division of Swiss pharmaceutical company, Novartis, and a global biosimilar supplier, announced yesterday that it has entered into a global commercialisation agreement for a proposed natalizumab biosimilar.
European biopharmaceutical company Polpharma Biologics SA reported on Tuesday the launch of a global commercialisation agreement with Sandoz AG for the natalizumab biosimilar for multiple sclerosis.
[USPRwire, Fri Aug 23 2019] Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company.
A white paper from the council titled "Failure to Launch: Patent Abuse Blocks Access to Biosimilars for America's Patients" notes that Congress has sought to spur biosimilar innovation and reduce drug spending on expensive brand-name biologies.
The "Biosimilar Market Trends 2019" report has been added to ResearchAndMarkets.com's offering.
A biosimilar is a product that is almost an identical copy of an original product that is manufactured by a different company.
The abstracts include real-world data from the company's biosimilar anti-TNF portfolio, which includes BENEPALI[TM] (etanercept), FLIXABI[TM] (infliximab) and IMRALDI[TM] (adalimumab).
Established in February 2012, Samsung Bioepis currently has four biosimilars approved and marketed across Europe, which include the anti-TNF trio of Benepali (etanercept), Flixabi (infliximab) and Imraldi (adalimumab), as well as an oncologic biosimilar, Ontruzant (trastuzumab).
Q A friend of mine has diabetes and says her doctor has started her on a 'biosimilar'.
Iselin, NJ, July 28, 2018 --(PR.com)-- As the world of biosimilars gains more traction and promise, and the FDA announces the release of a long-awaited Biosimilar Action Plan, SMi's 5th Annual Biosimilars USA Conference, taking place in New Jersey, USA on the 14th and 15th November 2018, aims to give crucial updates to biosimilar experts and scientific pioneers across the world in this rapidly evolving industry.
Leading chemical company LG Chem said Wednesday that it has started selling etanercept biosimilar products in Japan after obtaining regulatory approval to market the products there.
The National Assembly will host a conference on "The Biosimilar Medicines - Present and Future for Sustainable Health Care", reported BGNES.